Oedema, solid organ transplantation and mammalian target of rapamycin inhibitor/proliferation signal inhibitors (mTOR-I/PSIs)

Clinical Kidney Journal

Volumn 7, Issue 2, 2014, Pages 115-120

  Gharbi, Chems ^a   Gueutin, Victor ^a   Izzedine, Hassan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

angio oedema; everolimus; lymphoedema; oedema; proliferation signal inhibitor; sirolimus; VEGF C

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; COMPLEMENT COMPONENT C1S INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROLIFERATION SIGNAL INHIBITOR; PROLIFERATION SIGNAL PROTEIN; PROTEIN; PROTEIN INHIBITOR; RAPAMYCIN; RECOMBINANT PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANGIONEUROTIC EDEMA; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG INDUCED DISEASE; DRUG SAFETY; EDEMA; EYELID EDEMA; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LEG SWELLING; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; LYMPHEDEMA; LYMPHOCELE; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SOLID ORGAN TRANSPLANTATION;

EID: 84897380695     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfu001     Document Type: Review

References (67)

1. Valantine H, Zuckermann A. From clinical trials to clinical practice: an overview of Certican (everolimus) in heart transplantation. J Heart Lung Transplant 2005; 24(Suppl 4): S185-190 (Pubitemid 40379796)
2. Rostaing L, Kamar N. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 2010; 23: 133
3. Lehmkuhl H, Ross H, Arizon J et al. Comparability of pattern of occurrence of pericardial effusions between everolimus-and MMF-based regimen in de novo cardiac transplant recipients. J Heart Lung Transplant 2009; 28(2 Suppl 1): S170
4. Gullestad L, Iversen M, Mortensen SA et al. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial. Transplantation 2010; 89: 864-872
5. Gullestad L, Mortensen SA, Eiskjær H et al. Two-year outcomes in thoracic transplant recipients after conversion to everolimus with reduced calcineurin inhibitor within a multicenter, open-label, randomized trial. Transplantation 2010; 90: 1581-1589
6. Roman A, Ussetti P, Zurbano F et al. A retrospective 12-month study of conversion to everolimus in lung transplant recipients. Transplant Proc 2011; 43: 2693-2698
7. De Simone P, Metselaar HJ, Fischer L et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269
8. Alegre C, Jiménez C, Manrique A et al. Everolimus monotherapy or combined therapy in liver transplantation: indications and results. Transplant Proc 2013; 45: 1971-1974
9. Saliba F, De Simone P, Nevens F et al.; H2304 Study Group. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant 2013; 13: 1734-1745
10. Lorber MI, Mulgaonkar S, Butt KM et al.; B251 Study Group. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244-252 (Pubitemid 41061682)
11. Cotovio P, Neves M, Santos L et al. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Transplant Proc 2012; 44: 2966-2970
12. Shihab FS, Cibrik D, Chan L et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant 2013; 27: 217-226
13. Takahashi K, Uchida K, Yoshimura N et al. Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results. Transplant Res 2013; 2: 14
14. Moro JA, Almenar L, Martínez-Dolz L et al. mTOR inhibitors and unilateral edema. Rev Esp Cardiol 2008; 61: 987-988
15. Fukushima N, Saito S, Sakata Y et al. A case of everolimusassociated chylothorax in a cardiac transplant recipient. Transplant Proc 2013; 45: 3144-3146
16. Ersoy A, Koca N. Everolimus-induced lymphedema in a renal transplant recipient: a case report. Exp Clin Transplant 2012; 10: 296-298
17. Fuchs U, Zittermann A, Berthold HK et al. Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2005; 79: 981-983 (Pubitemid 40586875)
18. Aboujaoude W, Milgrom ML, Govani MV. Lymphedema associated with sirolimus in renal transplant recipients. Transplantation 2004; 77: 1094-1096 (Pubitemid 38508929)
19. Romagnoli J, Citterio F, Nanni G et al. Severe limb lymphedema in sirolimus-treated patients. Transplantation Proc 2005; 37: 834-836 (Pubitemid 40590717)
20. Al-Otaibi T, Ahamed N, Nampoory MR et al. Lymphedema: an unusual complication of sirolimus therapy. Transplant Proc 2007; 39: 1207-1210 (Pubitemid 46764895)
21. De Bartolomeis C, Collini A, Rumberger B et al. Generalized lymphedema in a sirolimus-treated renal transplant patient. Clin Transplant 2008; 22: 254-257 (Pubitemid 351420023)
22. Wadei H, Gruber SA, El-Amm JM et al. Sirolimus-induced angioedema. Am J Transplant 2004; 4: 1002-1005 (Pubitemid 38745600)
23. Mohaupt MG, Vogt B, Frey FJ. Sirolimus-associated eyelid edema in kidney transplant recipients. Transplantation 2001; 72: 162-164 (Pubitemid 32652524)
24. Papali A, Giannetti N, Cantarovich M. Unilateral upper extremity edema associated with sirolimus in a heart transplant patient. Transplantation 2007; 83: 240-241
25. Amante AJ, Kahan BD. Technical complications of renal transplantation. Surg Clin North Am 1994; 74: 1117
26. Khauli RB, Stoff JS, Lovewell T et al. Post-transplant lymphoceles: a critical look into the risk factors, pathophysiology and management. J Urol 1993; 150: 22
27. Malovrh M, Kandus A, Buturovic-Ponikvar J et al. Frequency and clinical influence of lymphoceles after kidney transplantation. Transplant Proc 1990; 22: 1423
28. Bry J, Hull D, Bartus SA et al. Treatment of recurrent lymphoceles following renal transplantation: remarsupialization with omentoplasty. Transplantation 1990; 49: 477
29. Schweizer RT, Cho S, Koutz SL et al. Lymphoceles following renal transplantation. Arch Surg 1972; 104: 42
30. Braun WE, Banowsky LH, Straffon RA et al. Lymphocytes associated with renal transplantation: report of 15 cases and review of the literature. Am J Med 1974; 57: 714
31. Zincke H, Woods JE, Leary FJ et al. Experience with lymphoceles after renal transplantation. Surgery 1975; 77: 444
32. Pollak R, Veremis SA, Maddux MS et al. The natural history of and therapy for perirenal fluid collections following renal transplantation. J Urol 1988; 140: 716
33. Vitko S, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626
34. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute allograft rejection: a randomized multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202 (Pubitemid 30446974)
35. Sansalone CV, Aseni P, Minetti E et al. Is lymphocele in renal transplantation an avoidable complication? Am J Surg 2000; 179: 182
36. Kay R, Fuchs E, Barry JM. Management of postoperative pelvic lymphoceles. Urology 1980; 15: 345
37. Rashid A, Posen G, Couture R et al. Accumulation of lymph around the transplanted kidney (lymphocele) mimicking renal allograft rejection. J Urol 1974; 111: 145
38. Bischof G, Rockenschaub S, Berlakovich G et al. Management of lymphoceles after kidney transplantation. Transpl Int 1998; 11: 277
39. Stephanian E, Matas AJ, Gores P et al. Retransplantation as a risk factor for lymphocele formation. Transplantation 1992; 53: 676
40. Martinez-Ocana JC, Lauzurica R, Castellote E et al. Adult polycystic kidney disease: a risk factor for lymphocele formation after renal transplantation? Transplant Proc 1995; 27: 2246
41. Teruel JL, Escobar EM, Quereda C et al. A simple and safe method for management of lymphocele after renal transplantation. J Urol 1983; 130: 1058
42. Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation 2002; 27: 804
43. Pascual J, Marcén R, Ortuño J. Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 2005; 79(Suppl): S80-S84 (Pubitemid 40656650)
44. Greager MA, Dzay VJ. Vascular disease of the extremities. In: Fauchi AS, Braunwald E, Isselbacher KJ et al. (eds). Harrison's Principles of Internal Medicine. New York: McGraw-Hill 1998, 1405 pp
45. Stoeltzing O, Meric-Bernstam F, Ellis LM. Intracellular signaling in tumor and endothelial cells: the expected and, yet again, the unexpected. Cancer Cell 2006; 10: 89-91 (Pubitemid 44175909)
46. Karkkainen MJ, Ferrell RE, Lawrence EC et al. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 2000; 25: 153-159 (Pubitemid 30394984)
47. Mäkinen T, Jussila L, Veikkola Tet al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001; 7: 199-205 (Pubitemid 32148487)
48. Huber S, Bruns CJ, Schmid G et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 2007; 71: 771-777 (Pubitemid 46624022)
49. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694-2700 (Pubitemid 39453021)
50. Steele GH, Adamkovic AB, Demopoulos LA et al. Pericardial effusion coincident with sirolimus therapy: a review of Wyeth's safety database. Transplantation 2008; 85: 645-647
51. Bouzas-Mosquera A, Crespo-Leiro MG, Paniagua MJ et al. Adverse effects of mammalian target of rapamycin inhibitors during the postoperative period after cardiac transplantation. Transplant Proc 2008; 40: 3027-3030
52. Agostoni A, Cicardi M. Drug-induced angioedema without urticaria. Drug Saf 2001; 24: 599-606
53. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992; 117: 234-242
54. Abbosh J, Anderson JA, Levine AB et al. Angiotensin converting enzyme inhibitor-induced angioedema more prevalent in transplant patients. Ann Allergy Asthma Immunol 1999; 82: 473-476 (Pubitemid 29242314)
55. Lykavieris P, Frauger E, Habes D et al. Angioedema in pediatric liver transplant recipients under tacrolimus immunosuppression. Transplantation 2003; 75: 152-155 (Pubitemid 36139712)
56. Burdese M, Rossetti M, Guarena C et al. Sirolimus and ACEinhibitors: a note of caution. Transplantation 2005; 79: 251-252
57. Stallone G, Infante B, Di Paolo S et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004; 19: 2906-2908 (Pubitemid 39480993)
58. Montalbano M, Neff GW, Yamashiki N et al. A retrospective review of liver transplant patients treated with sirolimus from a single center: an analysis of sirolimus-related complications. Transplantation 2004; 78: 264-268
59. Mahé E, Morelon E, Lechaton S et al. Angioedema in renal transplant recipients on sirolimus. Dermatology 2007; 214: 205-209 (Pubitemid 46457605)
60. Krikorian RK, Quick A, Tal A. Angioedema following the intravenous administration of metoprolol. Chest 1994; 106: 1922-1923 (Pubitemid 24375176)
61. Gainer JV, Nadeau JH, Ryder D et al. Increased sensitivity to bradykinin among African Americans. J Allergy Clin Immunol 1996; 98: 283-287 (Pubitemid 26326121)
62. Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensinconverting enzyme inhibitors. J Eval Clin Pract 2004; 10: 499-509 (Pubitemid 39469033)
63. Flockhart DA, Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension. Arch Intern Med 2002; 162: 405-412 (Pubitemid 34150641)
64. Lemahieu WP, Maes BD, Verbeke K et al. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporin vs tacrolimus vs sirolimus. Am J Transplant 2004; 4: 1514-1522 (Pubitemid 39159067)
65. Barshes NR, Goodpastor SE, Goss JA. Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation 2003; 76: 1649-1650 (Pubitemid 37549848)
66. Jeanmart H, Malo O, Carrier M et al. Comparative study of cyclosporine and tacrolimus vs newer immunosuppressants mycophenolate mofetil and rapamycin on coronary endothelial function. J Heart Lung Transplant 2002; 21: 990-998 (Pubitemid 35286683)
67. Mahé E, Morelon E, Lechaton S et al. Cutaneous adverse events in renal transplant recipients on sirolimus-based therapy. Transplantation 2005; 79: 476-482 (Pubitemid 40280181)